Back to results
US 10,472,405 B2Granted
Multivalent regulatory T cell modulators
AssigneeDelinia, Inc.
InventorsJeffrey Greve, Jungmin Kim, Niranjana Nagarajan, John Cho
Life of this patent
Estimating the term…
Abstract
This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.
Claims13
A fusion protein comprising:
- a) a human IL-2 protein domain wherein the human IL-2 protein domain comprises human IL-2 with a substitution selected from the group consisting of:
- T3A, N88R, N88G, D20H, C125S, Q126L, and Q126F, relative to the amino acid sequence of SEQ ID NO:
- 2;
- b) an immunoglobulin Fc protein domain;
- and
- c) an antibody specific for Interleukin 1 receptor-like 1 (ST2), or an antigen-binding fragment thereof.
3 more elements
A dimeric protein comprising a first fusion protein and a second fusion protein, wherein:
- a. each fusion protein comprises an immunoglobulin (IgG) Fc protein domain and at least one additional protein domain selected from the group consisting of
- i. a human IL-2 protein domain, wherein the human IL-2 protein domain comprises human IL-2 with a substitution selected from the group consisting of:
- T3A, N88R, N88G, D20H, C125S, Q126L, and Q126F, relative to the amino acid sequence of SEQ ID NO:
- 2;
- and
- ii. an antibody specific for Interleukin 1 receptor-like 1 (ST2), or an antigen-binding fragment thereof;
- and
- b. the dimeric protein comprises at least one of the human IL-2 protein domain and at least one of the antibody specific for ST2, or the antigen-binding fragment thereof.
5 more elements
Dependencies are inferred from the claim text.